US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

F/m Emerald Life Sciences Innovation ETF

43.94

+0.53661.24%

Post-market: 43.89-0.0476-0.11%16:15 EDT

Volume:600

Turnover:26.21K

Market Cap:122.02M

PE:- -

High:43.94

Open:43.38

Low:43.38

Close:43.40

52wk High:48.78

52wk Low:29.44

Shares:2.78M

Float Shares:2.78M

Volume Ratio:0.31

T/O Rate:0.02%

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Guardant Health Chief People Officer Terilyn Monroe Disposes of Common Shares Worth $7.61 Million

Travere Therapeutics Posts Corporate Overview on Rare Kidney Disease Growth Strategy, Filspari Expansion and Pipeline Updates

LivaNova Chief Innovation Officer Ahmet Tezel Disposes of Shares Worth $435,409.36

Press Release: Caribou Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update

Analysts Offer Insights on Healthcare Companies: TransMedics Group (TMDX), Spyre Therapeutics (SYRE) and COMPASS Pathways (CMPS)

BofA Securities Boosts Targets on Chinese CXO Players as Strong Biotech Funding Fuels R&D

Bank of America Securities Raises Targets for Chinese CXO Firms on Strong Biotech Funding

Travere Therapeutics Grants 38,940 Inducement RSUs to 12 New Employees

Travere Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS

Outlook Therapeutics Ends ATM Prospectus Amid Ongoing Risks

Small-Molecule Generic Drug CRO Firm Sees Extreme Share Price Swings, Warns of No Innovation Drug Exposure

Cogent Biosciences, Inc. : Leerink Partners Cuts Target Price to $60 from $72

THOMSON REUTERS

Analysts Offer Insights on Healthcare Companies: Travere Therapeutics (TVTX), Maze Therapeutics, Inc. (MAZE) and Immunome (IMNM)

Guardant Health Chief Commercial Officer Chris Freeman Disposes of $ 10.75 Million in Common Shares

Neurogene Advances Rett Gene Therapy Program and Extends Cash Runway to 2029

Xinjiang Bai Hua Clarifies No Role in Innovative Drug Development

Cogent Biosciences, Inc. : Guggenheim Raises Target Price to $52 from $45

THOMSON REUTERS

Analysts Offer Insights on Healthcare Companies: Spyre Therapeutics (SYRE), Stereotaxis (STXS) and Tvardi Therapeutics (TVRD)

AI Reshapes Drug Discovery Foundation, Domestic Industry Chain Expected to Benefit

Spyre Therapeutics Director Jeffrey W. Albers Disposes of USD 2.39 Million in Common Shares

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://hk.tigeractivity.com/stock/LFSC/news?page=10"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"LFSC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LFSC\",,,,,undefined,":{"symbol":"LFSC","market":"US","secType":"STK","nameCN":"F/m Emerald Life Sciences Innovation ETF","latestPrice":43.9376,"timestamp":1791230400000,"preClose":43.401,"halted":0,"volume":600,"hourTrading":{"tag":"盘后","latestPrice":43.89,"preClose":43.9376,"latestTime":"16:15 EDT","volume":10,"amount":439.13800000000003,"timestamp":1791231300295,"change":-0.0476,"changeRate":-0.001083,"amplitude":0.001083},"delay":0,"changeRate":0.012363770420036403,"floatShares":2777035,"shares":2777035,"eps":0,"marketStatus":"Post-Mkt","change":0.5366,"latestTime":"10-05 18:02:43 EDT","open":43.379,"high":43.9376,"low":43.379,"amount":26207,"amplitude":0.012871,"askPrice":65.1,"askSize":200,"bidPrice":42.75,"bidSize":12,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1791244800000},"marketStatusCode":4,"adr":0,"exchange":"NASDAQ","adjPreClose":43.401,"sharesOutstanding":2657035,"nav":43.44,"aum":120634400.4,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":43.89,"preClose":43.9376,"latestTime":"16:15 EDT","volume":10,"amount":439.13800000000003,"timestamp":1791231300295,"change":-0.0476,"changeRate":-0.001083,"amplitude":0.001083},"volumeRatio":0.314301},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LFSC\",,,,,undefined,":{"symbol":"LFSC","floatShares":2777035,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.314301,"shares":2777035,"dividePrice":0,"high":43.9376,"amplitude":0.012871,"preClose":43.401,"low":43.379,"week52Low":29.4441,"pbRate":"--","week52High":48.78,"institutionHeld":0,"latestPrice":43.9376,"committee":-0.886792,"eps":0,"divideRate":0,"volume":600,"delay":0,"ttmEps":0,"open":43.379,"prevYearClose":36.6147,"prevWeekClose":43.401,"prevMonthClose":44.5697,"prevQuarterClose":44.5697,"fiveDayClose":44.545,"twentyDayClose":46.1341,"sixtyDayClose":46.2892},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LFSC\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LFSC\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LFSC\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LFSC\",pageSize:20,pageCount:10,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2659719596","title":"Guardant Health Chief People Officer Terilyn Monroe Disposes of Common Shares Worth $7.61 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2659719596","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659719596?lang=en_us&edition=fundamental","pubTime":"2026-08-14 07:21","pubTimestamp":1786663307,"startTime":"0","endTime":"0","summary":"Guardant Health Chief People Officer Terilyn Monroe disposes of common shares worth $7.61 millionGuardant Health Chief People Officer Terilyn J. Monroe cut her direct common stock stake to 22,979 shar","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nNDL1rsYJl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Guardant Health Chief People Officer Terilyn Monroe Disposes of Common Shares Worth $7.61 Million","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LFSC","HELX","EKG","LU0109394709.USD","BK4551","LU0889565916.HKD","PTH","BK4196","BK4535","BK4588","FFOX","GDOC","GNMX","LU0320765992.SGD","BK4585","GNOM","GH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659956371","title":"Travere Therapeutics Posts Corporate Overview on Rare Kidney Disease Growth Strategy, Filspari Expansion and Pipeline Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2659956371","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659956371?lang=en_us&edition=fundamental","pubTime":"2026-08-14 07:14","pubTimestamp":1786662844,"startTime":"0","endTime":"0","summary":"Travere Therapeutics posts corporate overview on rare kidney disease growth strategy, FILSPARI expansion and pipeline updatesTravere outlined a growth plan centered on FILSPARI expansion in rare kidne","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nNDL6Fb4d0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LFSC","TVTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659162688","title":"LivaNova Chief Innovation Officer Ahmet Tezel Disposes of Shares Worth $435,409.36","url":"https://stock-news.laohu8.com/highlight/detail?id=2659162688","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659162688?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:05","pubTimestamp":1786651503,"startTime":"0","endTime":"0","summary":"LivaNova Chief Innovation Officer Ahmet Tezel disposes of shares worth $435,409.36Ahmet Tezel, chief innovation officer at LivaNova, reported a net decrease in ordinary share holdings to 6,090 on Aug.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nNDL3M7qWg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"LivaNova Chief Innovation Officer Ahmet Tezel Disposes of Shares Worth $435,409.36","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LFSC","LU2065171402.SGD","LU2065170008.USD","BK4082","LU2065171311.SGD","LU2065169927.USD","LIVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659162947","title":"Press Release: Caribou Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2659162947","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659162947?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:05","pubTimestamp":1786651500,"startTime":"0","endTime":"0","summary":"clinical trial were presented at the 2026 European Hematology Association.  Annual Meeting. Data presented reinforced vispa-cel is the only. single-dose, off-the-shelf therapy to demonstrate deep and durable. responses on par with autologous CAR-T cell therapies in second-line . large B cell lymphoma . Efficacy and safety data in 2L LBCL. patients who had received a single dose of 80 million optimized vispa-cel. -- Optimized vispa-cel is defined as cells from a donor younger than 30. years old with at least two matched human leukocyte antigen  alleles. between patient and donor. The 27-patient subgroup best represents the. treatment regimen and patient population for Caribou's planned ANTLER-3. -- Caribou previously reached alignment with the U.S. Food and Drug. Administration  regarding its planned ANTLER-3 pivotal phase 3. clinical trial design, which is expected to be a randomized, control","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNCR","BK4585","NVIB","BK4161","MEDX","LD","BK4211","BK4195","IDNA","BK4588","ORR","BK4230","PFS","FBT","CR","BK4539","SYNB","GDOC","CAR","BK4022","HYLG","TBXU","IBBQ","GNOM","BK4139","LFSC","IBB","CRBU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659165757","title":"Analysts Offer Insights on Healthcare Companies: TransMedics Group (TMDX), Spyre Therapeutics (SYRE) and COMPASS Pathways (CMPS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2659165757","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659165757?lang=en_us&edition=fundamental","pubTime":"2026-08-13 23:40","pubTimestamp":1786635611,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on TransMedics Group (TMDX), Spyre Therapeutics (SYRE) and COMPASS P...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-transmedics-group-tmdx-spyre-therapeutics-syre-and-compass-pathways-cmps-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-transmedics-group-tmdx-spyre-therapeutics-syre-and-compass-pathways-cmps-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4082","BK4139","LU2065731478.USD","XBI","LU2324357040.USD","SYRE","BK4588","LABU","PSIL","XLV","TMDX","LFSC","LU0029874061.USD","BK4585","BK4581","HCSG","CMPS","BK4137","LU0128526141.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155684243","title":"BofA Securities Boosts Targets on Chinese CXO Players as Strong Biotech Funding Fuels R&D","url":"https://stock-news.laohu8.com/highlight/detail?id=1155684243","media":"Deep News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1155684243?lang=en_us&edition=fundamental","pubTime":"2026-08-13 12:50","pubTimestamp":1786596641,"startTime":"0","endTime":"0","summary":"BofA Securities has released a report indicating that the Chinese CXO sector is poised to benefit from robust biotech venture capital funding. The bank notes that strong financing in the first half...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2242644610.SGD","BK1141","IDNA","LU0052750758.USD","LU1979443071.USD","LU2495084118.USD","PSCH","LU1046422090.SGD","IBRN","LU1303224171.USD","LU2125910500.SGD","MEDI","LU0456842615.SGD","LU1808992512.USD","SMCO","LU1997245177.USD","BMED","LU0348767384.USD","LU0611395673.USD","LU1719994722.HKD","CXO","LU1934453819.USD","XBIX","PSIL","BK0216","LU2045819591.USD","BK1576","LU2328871848.SGD","WX","BBC","LU0708995583.HKD","LU1997244956.HKD","LU0320764599.SGD","LU0348766576.USD","IE00B5MMRT66.SGD","SURI","APXH","BK1583","IE00BPRC5H50.USD","LU1997245094.SGD","161027","IE00B543WZ88.USD","LU1770034418.SGD","FHLC","LU0700851271.USD","02359","603259","LU1969619763.USD","LU2488822045.USD","LU1251922891.USD","LFSC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111112440","title":"Bank of America Securities Raises Targets for Chinese CXO Firms on Strong Biotech Funding","url":"https://stock-news.laohu8.com/highlight/detail?id=1111112440","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1111112440?lang=en_us&edition=fundamental","pubTime":"2026-08-13 10:35","pubTimestamp":1786588544,"startTime":"0","endTime":"0","summary":"A report from Bank of America Securities indicates that Chinese CRO/CDMO companies are poised to benefit from robust first-half funding in the global and Chinese biotech sectors, along with active...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0051755006.USD","SURI","LU1997245094.SGD","CXO","LU1251922891.USD","PSCH","LU2328871848.SGD","LU0417516902.SGD","LU0456827905.SGD","LU0700851271.USD","LFSC","02359","LU0456842615.SGD","PSIL","BK1589","KURE","LU0320764599.SGD","SG9999002463.SGD","LU2125910500.SGD","LU2039709279.SGD","LU0043850808.USD","XBIX","IBRN","LU1808992512.USD","LU1242518931.SGD","IE00B543WZ88.USD","LU1934453819.USD","BMED","LU0856984785.SGD","LU1719994722.HKD","LU0307460666.USD","LU0326950275.SGD","LU1242518857.USD","LU0181495838.USD","LU0516423091.SGD","LU1794554557.SGD","LU1770034418.SGD","LU1303224171.USD","03759","LU0819121731.USD","LU1720050803.USD","BBC","LU0348825331.USD","LU1880383366.USD","APXH","LU0588546209.SGD","LU0348735423.USD","LU0572944931.SGD","LU2045819591.USD","LU1688375341.USD","LU0456846285.SGD","LU2488822045.USD","LU0052750758.USD","LU0029874061.USD","BK1576","LU0327786744.USD","IDNA","LU0516423174.USD","LU0979878070.USD","BK0216","LU1046422090.SGD","LU1969619763.USD","LU1997245177.USD","LU0039217434.USD","LU0348767384.USD","02269","LU0516422366.SGD","IE00B5MMRT66.SGD","MEDI","LU0359201612.USD","LU0128526141.USD","161027","BK1521","LU1979443071.USD","BK1583","SG9999002562.SGD","SMCO","LU0359202008.SGD","LU0611395673.USD","LU0823426480.USD","LU0708995583.HKD","LU0348766576.USD","BK1141","LU0823426308.USD","BK1610","LU0140636845.USD","FHLC","IE00B0JY6N72.USD","603259","LU2495084118.USD","LU2242644610.SGD","IE00BPRC5H50.USD","LU3063872942.SGD","LU1997244956.HKD","LU0516422952.EUR","LU0516422440.USD","WX","LU0417516738.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659188087","title":"Travere Therapeutics Grants 38,940 Inducement RSUs to 12 New Employees","url":"https://stock-news.laohu8.com/highlight/detail?id=2659188087","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659188087?lang=en_us&edition=fundamental","pubTime":"2026-08-13 05:00","pubTimestamp":1786568413,"startTime":"0","endTime":"0","summary":"Travere Therapeutics grants 38,940 inducement RSUs to 12 new employeesTravere Therapeutics granted inducement restricted stock units covering 38,940 common shares to 12 new employees on Aug. 10, 2026.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nNDL1ttjYP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LFSC","BK4139","TVTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659712188","title":"Travere Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2659712188","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659712188?lang=en_us&edition=fundamental","pubTime":"2026-08-13 05:00","pubTimestamp":1786568400,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nTUA6BNMJD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TVTX","LFSC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659926188","title":"Outlook Therapeutics Ends ATM Prospectus Amid Ongoing Risks","url":"https://stock-news.laohu8.com/highlight/detail?id=2659926188","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659926188?lang=en_us&edition=fundamental","pubTime":"2026-08-13 04:37","pubTimestamp":1786567029,"startTime":"0","endTime":"0","summary":"The latest update is out from Outlook Therapeutics ( ($OTLK) ). On July 24, 2026, Outlook Therapeutics announced U.S. FDA approval of LYTENAVA (bev...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/outlook-therapeutics-ends-atm-prospectus-amid-ongoing-risks?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/outlook-therapeutics-ends-atm-prospectus-amid-ongoing-risks?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IBB","LABU","NVIB","IDNA","BK4139","LFSC","MEDI","MRNY","LENZ","GNMX","RSPH","IEIH","FRTY","MRNX","GDOC","TBXU","BK4539","XLVX","BBP","BK4588","PSCH","PINK","SYNB","IYH","BK4585","BMED","TECB","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142463773","title":"Small-Molecule Generic Drug CRO Firm Sees Extreme Share Price Swings, Warns of No Innovation Drug Exposure","url":"https://stock-news.laohu8.com/highlight/detail?id=1142463773","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1142463773?lang=en_us&edition=fundamental","pubTime":"2026-08-12 22:10","pubTimestamp":1786543834,"startTime":"0","endTime":"0","summary":"Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd. (600721.SH) issued a statement on August 12, revealing that its stock price has experienced an unusual surge, with cumulative closing price gains exceeding...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0102","BK4588","APXH","BK0216","LFSC","600721","WRND","BIOY","BK4585","GDOC","SBIO","XLVI","PBE","GSKH","IBB","BBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658970686","title":"Cogent Biosciences, Inc. : Leerink Partners Cuts Target Price to $60 from $72","url":"https://stock-news.laohu8.com/highlight/detail?id=2658970686","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658970686?lang=en_us&edition=fundamental","pubTime":"2026-08-12 21:00","pubTimestamp":1786539637,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nFWN4491GS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LFSC","COGT","BK4139","BK4505","CANC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658974286","title":"Analysts Offer Insights on Healthcare Companies: Travere Therapeutics (TVTX), Maze Therapeutics, Inc. (MAZE) and Immunome (IMNM)","url":"https://stock-news.laohu8.com/highlight/detail?id=2658974286","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658974286?lang=en_us&edition=fundamental","pubTime":"2026-08-12 19:40","pubTimestamp":1786534824,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Travere Therapeutics (TVTX), Maze Therapeutics, Inc....","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-travere-therapeutics-tvtx-maze-therapeutics-inc-maze-and-immunome-imnm-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-travere-therapeutics-tvtx-maze-therapeutics-inc-maze-and-immunome-imnm-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","HCSG","BK4588","FFTY","BK4139","BK4137","LABU","BK4581","BK4007","LFSC","MAZE","IMNM","LU0029874061.USD","LU0128526141.USD","XLV","BK4563","XBI","TVTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658949165","title":"Guardant Health Chief Commercial Officer Chris Freeman Disposes of $ 10.75 Million in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2658949165","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658949165?lang=en_us&edition=fundamental","pubTime":"2026-08-12 06:23","pubTimestamp":1786487005,"startTime":"0","endTime":"0","summary":"Guardant Health Chief Commercial Officer Chris Freeman disposes of $ 10.75 million in common sharesGuardant Health Chief Commercial Officer Chris Freeman exercised stock options for 63,605 shares on A","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nNDL4khYKk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Guardant Health Chief Commercial Officer Chris Freeman Disposes of $ 10.75 Million in Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","EKG","GNOM","BK4535","GH","BK4196","BK4588","LFSC","PTH","GNMX","BK4551","GDOC","FFOX","LU0109394709.USD","BK4585","LU0320765992.SGD","HELX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658657916","title":"Neurogene Advances Rett Gene Therapy Program and Extends Cash Runway to 2029","url":"https://stock-news.laohu8.com/highlight/detail?id=2658657916","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658657916?lang=en_us&edition=fundamental","pubTime":"2026-08-11 22:01","pubTimestamp":1786456868,"startTime":"0","endTime":"0","summary":"Neurogene ( ($NGNE) ) just unveiled an announcement. Neurogene reported strong progress in its NGN-401 gene therapy program for Rett syndrome, high...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/neurogene-advances-rett-gene-therapy-program-and-extends-cash-runway-to-2029?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/neurogene-advances-rett-gene-therapy-program-and-extends-cash-runway-to-2029?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4588","CNCR","IBBQ","FBT","GNOM","IBB","LFSC","SYNB","TBXU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174341976","title":"Xinjiang Bai Hua Clarifies No Role in Innovative Drug Development","url":"https://stock-news.laohu8.com/highlight/detail?id=1174341976","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1174341976?lang=en_us&edition=fundamental","pubTime":"2026-08-11 20:08","pubTimestamp":1786450094,"startTime":"0","endTime":"0","summary":"Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd. (600721.SH) has issued a stock trading risk warning announcement, stating that it is a CRO enterprise primarily focused on the research and development of...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LFSC","XLVI","GDOC","BBP","BK0102","600721","PBE","GSKH","BK4588","IBB","WRND","SBIO","APXH","BK0216","BIOY","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658997334","title":"Cogent Biosciences, Inc. : Guggenheim Raises Target Price to $52 from $45","url":"https://stock-news.laohu8.com/highlight/detail?id=2658997334","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658997334?lang=en_us&edition=fundamental","pubTime":"2026-08-11 19:35","pubTimestamp":1786448103,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nFWN44813Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4505","CANC","BK4139","LFSC","COGT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658372967","title":"Analysts Offer Insights on Healthcare Companies: Spyre Therapeutics (SYRE), Stereotaxis (STXS) and Tvardi Therapeutics (TVRD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2658372967","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658372967?lang=en_us&edition=fundamental","pubTime":"2026-08-11 14:30","pubTimestamp":1786429817,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Spyre Therapeutics (SYRE), Stereotaxis (STXS) and Tv...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-spyre-therapeutics-syre-stereotaxis-stxs-and-tvardi-therapeutics-tvrd-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-spyre-therapeutics-syre-stereotaxis-stxs-and-tvardi-therapeutics-tvrd-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","STXS","BK4137","HCSG","BK4585","SYRE","LU0128526141.USD","BK4082","BK4139","XBI","LABU","LFSC","XLV","TVRD","BK4007","LU0029874061.USD","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118729610","title":"AI Reshapes Drug Discovery Foundation, Domestic Industry Chain Expected to Benefit","url":"https://stock-news.laohu8.com/highlight/detail?id=1118729610","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1118729610?lang=en_us&edition=fundamental","pubTime":"2026-08-11 14:12","pubTimestamp":1786428745,"startTime":"0","endTime":"0","summary":"A research report from Orient Securities Company Limited highlights that as global regulatory shifts accelerate, the large-scale application of AI in pharmaceuticals is rapidly advancing. It has...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SBIO","03958","BK0183","QTOC","GDOC","WRND","GSKH","BIOY","BK0012","BK1564","CHAT","LFSC","APXH","XLVI","IBB","BK4585","AGIX","AIPO","ARTY","BK4588","VTHR","BBP","BK1147","600958","BK0188","BK0276","BK0028","PBE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658696533","title":"Spyre Therapeutics Director Jeffrey W. Albers Disposes of USD 2.39 Million in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2658696533","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658696533?lang=en_us&edition=fundamental","pubTime":"2026-08-11 09:32","pubTimestamp":1786411952,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics director Jeffrey W. Albers disposes of USD 2.39 million in common sharesSpyre Therapeutics director Jeffrey W. Albers exercised stock options to buy 5,000 common shares at USD 10.39","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nNDL7DPBBq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Spyre Therapeutics Director Jeffrey W. Albers Disposes of USD 2.39 Million in Common Shares","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SYRE","BK4139","LFSC"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":10,"totalSize":200,"code":"91000000","status":"200"}]}}